Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

They invest in public stocks and bonds, and their clients are increasingly sensitive to costs. Their most popular products these days are passive index trackers with razor-thin fees, often just a few ...

The Aiken County Historical Museum will continue its Winter Lecture Series at 3 p.m. Sunday, Feb. 23. The program will be The ...

Hexaware Technologies debuted positively on the National Stock Exchange (NSE) on Wednesday, listing shares at a 5.3% premium ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...